atrasentan hydrochloride

DRUG5 trials

Sponsors

National Cancer Institute (NCI), Eastern Cooperative Oncology Group, Abbott, SWOG Cancer Research Network, Vanderbilt-Ingram Cancer Center

Conditions

Brain and Central Nervous System TumorsFallopian Tube CancerKidney CancerMetastatic CancerOvarian CancerPeritoneal Cavity CancerProstate Cancer

Phase 1

Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma

CompletedNCT00017264

National Cancer Institute (NCI)Brain and Central Nervous System Tumors

Start: 2002-06-30Updated: 2009-01-13

Phase 2

Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer

CompletedNCT00039429

Eastern Cooperative Oncology GroupKidney Cancer

Start: 2003-07-14Target: 180Updated: 2023-06-22

Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma

TerminatedNCT00653328

Vanderbilt-Ingram Cancer CenterFallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer

Start: 2003-05-31End: 2009-03-31Updated: 2012-05-23

Phase 3

Atrasentan in Treating Patients With Prostate Cancer

CompletedNCT00046943

AbbottProstate Cancer

Start: 2002-09-30Updated: 2011-02-21

S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy

CompletedNCT00134056

SWOG Cancer Research NetworkMetastatic Cancer, Prostate Cancer

Start: 2006-08-31End: 2016-02-29Updated: 2021-10-27

Related Papers

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.

2013-07-17115 citations